Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations

LAUSANNE, Switzerland, May 15 /PRNewswire/ -- Debiopharm Group
(Debiopharm), a global independent biopharmaceutical development specialist
focusing on serious medical conditions and particularly oncology, announced
the signature of a license agreement with its long-term European
pharmaceutical partner, for the marketing of Salvacyl(R)/Moapar(R) 3-month
formulation, a gonadotropin releasing hormone (GnRH) agonist analogue,
effective in the treatment of severe sexual deviations in adult men by
inducing and maintaining a reversible reduction of testosterone to castrate
serum levels. Debiopharm has developed and received marketing
authorisations for Salvacyl / Moapar in nine major European countries,
including France, Germany, UK, Sweden, Norway, Denmark, Belgium, the
Netherlands and Finland.

"There is a genuine unmet medical and social need for the treatment of
sexual deviations. Not many pharma companies are willing or courageous
enough to provide this type of treatment but we feel that we have a
responsibility to help doctors and patients with the tools they need, even
if it is difficult or controversial," said Rolland-Yves Mauvernay,
President and Founder of Debiopharm Group.

About Salvacyl(R)/Moapar(R)

In the treatment of sexual deviations in men, administration of
Salvacyl(R)/Moapar(R) every 3 months is an advantage over daily oral forms
or intra-muscular weekly injections required with antiandrogens such as
cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA) and there
are fewer side effects.

Two studies have shown that regular injections of the active
ingredient, triptorelin, over a period of eight months to seven years in
male patients with sexual deviations demonstrated a good efficacy and
safety profile. Triptorelin produced reversible serum castrate testosterone
levels (defined as less than or equal to 1.735 nmol/L) in all patients, and
concurrently with the decrease in testosterone levels, triptorelin
treatment reduced deviant sexual behaviours in 35/36 patients with severe
sexual deviations.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist
that in-licenses promising biologics and small molecule drug candidates.
Debiopharm develops its products for global registration and maximum
commercial potential for out-licensing to pharmaceutical partners for sales
and marketing.

Debiopharm independently funds the worldwide development of all of its
products while providing expertise in pre-clinical and clinical trials,
manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm
has developed three products with global combined sales in excess of .65
billion in 2007.



For more information on Debiopharm Group, please visit:
http://www.debiopharm.com.

Debiopharm S.A. Contacts

Kim Bill
VP, Corporate Development
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
kbill@debiopharm.com

Additional Media Contacts

In London

Maitland
Brian Hudspith
Tel: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York

Russo Partners, LLC
Wendy Lau
Tel: +1-212-845-4272
Fax: +1-212-845-4260
wendy.lau@russopartnersllc.com





See Also

• Elsie & Marvin Dekelboum Family Foundation Gives $1 Million To Heart Institute At Children’s National Medical Center
• Laserfiche Sets New Bar for ECM Systems
• Bug Bam's All Natural Mosquito Repelling Grids Match Effectiveness of Topical Repellants
• The 50 in 50 to hit golf Courses all Across America to Raise Money and Awareness for Cancer Prevention

Via: Healthcare